CL2017002731A1 - Adenovirus oncolítico que codifica una proteína b7 - Google Patents

Adenovirus oncolítico que codifica una proteína b7

Info

Publication number
CL2017002731A1
CL2017002731A1 CL2017002731A CL2017002731A CL2017002731A1 CL 2017002731 A1 CL2017002731 A1 CL 2017002731A1 CL 2017002731 A CL2017002731 A CL 2017002731A CL 2017002731 A CL2017002731 A CL 2017002731A CL 2017002731 A1 CL2017002731 A1 CL 2017002731A1
Authority
CL
Chile
Prior art keywords
protein
oncolytic adenovirus
adenovirus encoding
viruses
compositions
Prior art date
Application number
CL2017002731A
Other languages
English (en)
Inventor
Brian Robert Champion
Alice Claire Noel Bromley
Original Assignee
Psioxus Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1507419.8A external-priority patent/GB201507419D0/en
Priority claimed from GBGB1516936.0A external-priority patent/GB201516936D0/en
Priority claimed from GBGB1522013.0A external-priority patent/GB201522013D0/en
Application filed by Psioxus Therapeutics Ltd filed Critical Psioxus Therapeutics Ltd
Publication of CL2017002731A1 publication Critical patent/CL2017002731A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

<p>La presente descripción proporciona un adenovirus de replicación oncolítico competente con selectividad para células cancerosas, donde el adenovirus comprende un transgén bajo el control de un promotor endógeno del virus, en el que el transgén comprende una secuencia de ADN que codifica una proteína B7 o un fragmento activo de la misma, composiciones que comprende los mismos, métodos para generar los virus, y uso de los virus y las composiciones en tratamiento, particularmente en el tratamiento del cáncer.</p>
CL2017002731A 2015-04-30 2017-10-26 Adenovirus oncolítico que codifica una proteína b7 CL2017002731A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1507419.8A GB201507419D0 (en) 2015-04-30 2015-04-30 Virus
GBGB1516936.0A GB201516936D0 (en) 2015-09-24 2015-09-24 Virus
GBGB1522013.0A GB201522013D0 (en) 2015-12-14 2015-12-14 Virus

Publications (1)

Publication Number Publication Date
CL2017002731A1 true CL2017002731A1 (es) 2018-06-08

Family

ID=56008588

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2017002731A CL2017002731A1 (es) 2015-04-30 2017-10-26 Adenovirus oncolítico que codifica una proteína b7
CL2018000587A CL2018000587A1 (es) 2015-04-30 2018-03-05 Adenovirus oncolítico que codifica una proteína b7 (divisional de sol. n° 2731-2017)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2018000587A CL2018000587A1 (es) 2015-04-30 2018-03-05 Adenovirus oncolítico que codifica una proteína b7 (divisional de sol. n° 2731-2017)

Country Status (31)

Country Link
US (6) US11000559B2 (es)
EP (2) EP3391892A1 (es)
JP (3) JP6931229B2 (es)
KR (4) KR102854512B1 (es)
CN (2) CN107690479B (es)
AU (3) AU2016256582B2 (es)
BR (2) BR112017023171A2 (es)
CA (1) CA2984038C (es)
CL (2) CL2017002731A1 (es)
CO (1) CO2017010831A2 (es)
CY (1) CY1122833T1 (es)
DK (1) DK3288573T3 (es)
EA (1) EA037611B1 (es)
ES (1) ES2780366T3 (es)
HR (1) HRP20200439T1 (es)
HU (1) HUE048320T2 (es)
IL (3) IL284375B (es)
LT (1) LT3288573T (es)
MX (1) MX2017013684A (es)
MY (1) MY183703A (es)
PE (2) PE20181140A1 (es)
PH (1) PH12017501942A1 (es)
PL (1) PL3288573T3 (es)
PT (1) PT3288573T (es)
RS (1) RS60105B1 (es)
SA (2) SA520412637B1 (es)
SG (3) SG10201803081TA (es)
SI (1) SI3288573T1 (es)
SM (1) SMT202000222T1 (es)
WO (1) WO2016174200A1 (es)
ZA (1) ZA201801589B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2914790C (en) 2013-06-14 2024-02-27 Psioxus Therapeutics Limited A dosing regime and formulations for type b adenoviruses
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
HUE035875T2 (hu) 2013-10-25 2018-06-28 Psioxus Therapeutics Ltd Heterológ géneket tartalmazó onkolitikus adenovírusok
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
HRP20200439T1 (hr) 2015-04-30 2020-06-12 Psioxus Therapeutics Limited Onkolitički adenovirus koji kodira protein b7
US10273281B2 (en) 2015-11-02 2019-04-30 Five Prime Therapeutics, Inc. CD80 extracellular domain polypeptides and their use in cancer treatment
BR112018012180A2 (pt) * 2015-12-17 2018-12-04 Psioxus Therapeutics Ltd vírus de codificação de um anticorpo ou fragmento de complexo anti-tcr
JP7466271B2 (ja) * 2016-03-31 2024-04-12 ザ ヨーロピアン モレキュラー バイオロジー ラボラトリー アデノウイルスコートタンパク質由来送達賦形剤
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
IL303187A (en) 2016-08-29 2023-07-01 Akamis Bio Ltd Adenovirus with bispecific T cell activator
ES2981703T3 (es) 2016-09-02 2024-10-10 Lentigen Tech Inc Composiciones y métodos para tratar cáncer con DuoCars
JP7138946B2 (ja) * 2016-09-27 2022-09-20 セイター セラピューティクス エルエルシー 最適化された腫瘍溶解性ウイルスおよびその使用
WO2018083257A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083258A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018083259A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
JP7724601B2 (ja) * 2017-02-03 2025-08-18 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 腫瘍溶解性ウイルス療法
KR20190139216A (ko) 2017-04-28 2019-12-17 파이브 프라임 테라퓨틱스, 인크. Cd80 세포외 도메인 폴리펩티드를 이용한 치료 방법
EP3630144A4 (en) * 2017-05-25 2021-03-31 University of Central Florida Research Foundation, Inc. NEW ONCOLYTIC VIRUSES TO SENSITIZE TUMOR CELLS TO DESTRUCTION BY NATURAL KILLER CELLS
JP7216668B2 (ja) 2017-05-26 2023-02-01 エピセントアールエックス，インコーポレイテッド 導入遺伝子を保持する組換えアデノウイルス
DK3630143T5 (da) 2017-06-01 2024-09-02 Akamis Bio Ltd Onkolytisk virus og fremgangsmåde
WO2019147921A1 (en) * 2018-01-26 2019-08-01 Nantcell, Inc. Rapid verification of virus particle production for a personalized vaccine
GB201801614D0 (en) * 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
WO2019173334A1 (en) * 2018-03-05 2019-09-12 The Schepens Eye Research Institute, Inc. Engineered vegf variants for retinal neuroprotection, promotion of axon growth and axon regeneration
KR20200136972A (ko) * 2018-03-30 2020-12-08 도모키 도도 종창 발생 억제형 종양 용해성 바이러스
WO2020052551A1 (en) * 2018-09-10 2020-03-19 Genesail Biotech (Shanghai) Co. Ltd. A modified oncolytic virus, composition and use thereof
US12589132B2 (en) 2019-02-22 2026-03-31 Five Prime Therapeutics, Inc. CD80 extracellular domain Fc fusion proteins for treating PD-L1 negative tumors
EA202192420A1 (ru) * 2019-03-05 2021-12-13 Эмджен Инк. Применение онколитических вирусов для лечения рака
EP3725323A1 (en) * 2019-04-17 2020-10-21 Targovax Asa Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada
US20220249127A1 (en) * 2019-05-14 2022-08-11 Oncolys Biopharma Inc. Method for administering oncolytic virus to tumor tissue, and device for administration
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
GB201909081D0 (en) 2019-06-25 2019-08-07 Psioxus Therapeutics Ltd Method
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
GB202102049D0 (en) 2021-02-13 2021-03-31 Psioxus Therapeutics Ltd Viruses
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
WO2022252185A1 (zh) * 2021-06-03 2022-12-08 上海允英生物医药科技有限公司 溶瘤病毒载体及其应用
CA3233100A1 (en) 2021-09-23 2023-03-30 Sagittarius Bio, Inc. Adenoviruses and methods for using adenoviruses
EP4499846A1 (en) * 2022-03-25 2025-02-05 Universität Zürich Adenoviral mediated targeting of activated immune cells
AU2024277678A1 (en) 2023-05-25 2025-11-27 Dispatch Biotherapeutics, Inc. Synthetic cancer antigens as targets for treating cancers
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
SK282843B6 (sk) 1993-07-13 2002-12-03 Rhone-Poulenc Rorer S. A. Defektný rekombinantný adenovírus a farmaceutický prostriedok s jeho obsahom
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US5677170A (en) 1994-03-02 1997-10-14 The Johns Hopkins University In vitro transposition of artificial transposons
US5877011A (en) 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
CN1242051A (zh) 1996-12-31 2000-01-19 昂尼克斯药物公司 用于肿瘤治疗和预防的致细胞病变病毒
EP1036183B1 (en) 1997-02-20 2007-10-03 The Johns Hopkins University School Of Medicine Mutations in atp-dependent transposition proteins that reduce target-site specificity
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US6291214B1 (en) 1998-05-11 2001-09-18 Glaxo Wellcome Inc. System for generating recombinant viruses
US20020019051A1 (en) 1998-05-27 2002-02-14 Monika Lusky Chimeric adenoviral vectors
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
CN1110553C (zh) 1998-07-15 2003-06-04 杭州赛狮生物技术开发有限公司 基因工程腺病毒及其用途
US6455314B1 (en) 1998-09-11 2002-09-24 Genvec, Inc. Alternatively targeted adenovirus
DK1137792T3 (da) 1998-12-09 2007-09-10 Us Gov Health & Human Serv En rekombinant vektor, der udtrykker adskillige costimulatoriske molekyler, og anvendelser deraf
ES2372823T3 (es) 1999-05-17 2012-01-26 Crucell Holland B.V. Adenovirus recombinante del serotipo ad11.
EP1181382B1 (en) 1999-06-01 2005-03-23 The University of Washington Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
US7396679B2 (en) 1999-11-15 2008-07-08 Onyx Pharmaceuticals, Inc. Oncolytic adenovirus
GB2375113B (en) 2000-01-21 2004-10-20 Biovex Ltd A modified, oncolytic, non-laboratory HSV strain and its use in treating cancer
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
WO2001092549A2 (en) 2000-05-31 2001-12-06 Genvec, Inc. Method and composition for targeting an adenoviral vector
ATE449859T1 (de) 2001-01-04 2009-12-15 Goeran Wadell Virusvektor zur gentherapie
US20050175589A1 (en) 2001-07-13 2005-08-11 Btg International Limited Anti-neoplastic viral agents
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP1327688A1 (en) 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviruses with enhanced lytic potency
CA2474777A1 (en) 2002-02-01 2003-08-07 Transgene S.A. Adenoviral vectors for modulating the cellular activities associated with pods
US20060147420A1 (en) 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
US7858367B2 (en) 2002-04-30 2010-12-28 Duke University Viral vectors and methods for producing and using the same
CN1705740B (zh) * 2002-10-15 2013-07-24 佩尔·松内·霍尔姆 具有反向基因表达的腺病毒及其应用
US20040167088A1 (en) 2003-02-25 2004-08-26 Genvec, Inc. Method of using adenoviral vectors with increased persistence in vivo
WO2004087930A1 (en) 2003-03-28 2004-10-14 Saint Louis University Adenovirus replication-competent vectors expressing trail
US20050136035A1 (en) 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
US20050036989A1 (en) 2003-07-18 2005-02-17 Onyx Pharmaceuticals, Inc. Subgroup B adenoviral vectors for treating disease
US20050186178A1 (en) * 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
US20080292592A1 (en) 2004-04-30 2008-11-27 Sunil Chada Oncolytic Adenovirus Armed with Therapeutic Genes
BRPI0510475B8 (pt) * 2004-05-26 2021-05-25 Bayer Pharma AG adenovírus quimérico recombinante, uso do mesmo no tratamento de câncer e métodos de inibição de crescimento de uma célula de câncer, de fornecimento de uma proteína terapêutica a uma célula e para o isolamento do adenovírus
CN100361710C (zh) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
US20060292682A1 (en) * 2004-07-22 2006-12-28 Hawkins Lynda K Addition of transgenes into adenoviral vectors
CN101068933A (zh) * 2004-08-25 2007-11-07 细胞基因系统有限公司 用于肿瘤细胞增强转导的纤维修饰的腺病毒载体
EP1784493A2 (en) * 2004-09-01 2007-05-16 The Government of the United States of America as Represented by The Department of Health and Human Services Adenoviral vectors able to transduce apcs, potential use in immune response generation
US20090208924A1 (en) 2004-12-01 2009-08-20 Bayer Schering Pharma Aktiengesellschaft Generation of Replication Competent Viruses for Therapeutic Use
BRPI0615400A2 (pt) 2005-08-31 2011-05-17 Genvec Inc vacinas para malária baseadas em vetor adenoviral
DE102005055128B4 (de) 2005-11-15 2015-04-02 Universität Rostock Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor
ES2304281B1 (es) 2006-02-01 2009-08-12 Dnatrix Inc. Adenovirus oncoliticos para el tratamiento del cancer.
WO2008080003A2 (en) 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Generation of oncolytic adenoviruses and uses thereof
EP2296678A4 (en) 2008-05-27 2012-03-21 Oncolytics Biotech Inc MODULATION OF INTERSTITIAL PRESSURE AND ONCOLYTIC VIRUS RELIEF AND DISTRIBUTION
CN101381742A (zh) * 2008-10-23 2009-03-11 浙江理工大学 晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
WO2011043719A1 (en) * 2009-10-05 2011-04-14 Ya-Fang Mei Replicating viral vectors for gene therapy
CN103237889B (zh) 2010-08-16 2017-04-05 萨克生物研究学院 腺病毒组装方法
US20130323205A1 (en) * 2010-09-24 2013-12-05 Oncos Therapeutics Oy Oncolytic adenoviral vectors and methods and uses related thereto
US20130243731A1 (en) 2010-09-24 2013-09-19 Oncos Therapeutics Oy Oncolytic adenoviral vectors coding for monoclonal anti-ctla-4 antibodies
JP2015507604A (ja) 2011-11-14 2015-03-12 リジェネレイティブ サイエンシーズ， エルエルシー 懸濁粒子送達システムおよび方法
CN102586327B (zh) 2012-01-18 2013-09-11 陕西师范大学 一步法构建携带外源基因的d24纤维蛋白修饰的条件复制型腺病毒载体及其应用
WO2014138314A1 (en) 2013-03-05 2014-09-12 Baylor College Of Medicine Oncolytic virus
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
HUE035875T2 (hu) * 2013-10-25 2018-06-28 Psioxus Therapeutics Ltd Heterológ géneket tartalmazó onkolitikus adenovírusok
CN106029889A (zh) 2013-11-22 2016-10-12 德那翠丝有限公司 表达免疫细胞刺激受体激动剂的腺病毒
GB201406608D0 (en) * 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
GB201510197D0 (en) * 2014-06-12 2015-07-29 Psioxus Therapeutics Ltd Method of treating ovarian cancer
GB201503500D0 (en) 2015-03-02 2015-04-15 Ucl Business Plc Cell
AU2016232009B2 (en) 2015-03-17 2021-07-15 Tilt Biotherapeutics Oy Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto
HRP20200439T1 (hr) 2015-04-30 2020-06-12 Psioxus Therapeutics Limited Onkolitički adenovirus koji kodira protein b7
BR112018012180A2 (pt) 2015-12-17 2018-12-04 Psioxus Therapeutics Ltd vírus de codificação de um anticorpo ou fragmento de complexo anti-tcr
CN109312364A (zh) 2016-03-18 2019-02-05 河谷细胞有限公司 用于感染树突状细胞的多模式载体
IL303187A (en) 2016-08-29 2023-07-01 Akamis Bio Ltd Adenovirus with bispecific T cell activator
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
WO2018075978A1 (en) 2016-10-20 2018-04-26 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
WO2018083258A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018083257A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083259A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
DK3630143T5 (da) * 2017-06-01 2024-09-02 Akamis Bio Ltd Onkolytisk virus og fremgangsmåde
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation

Also Published As

Publication number Publication date
US20210338753A1 (en) 2021-11-04
CN107690479A (zh) 2018-02-13
PE20181140A1 (es) 2018-07-17
US10322152B2 (en) 2019-06-18
CA2984038C (en) 2023-01-03
MX2017013684A (es) 2018-08-28
SG10201803081TA (en) 2018-06-28
SA520412637B1 (ar) 2022-03-01
PT3288573T (pt) 2020-03-25
EA201791971A1 (ru) 2018-04-30
KR20180022638A (ko) 2018-03-06
SG10201901482XA (en) 2019-03-28
SA517390260B1 (ar) 2021-11-10
IL255286B (en) 2021-01-31
HRP20200439T1 (hr) 2020-06-12
JP7162929B2 (ja) 2022-10-31
US10124028B2 (en) 2018-11-13
JP6928380B2 (ja) 2021-09-01
IL284375B (en) 2022-07-01
AU2020223665A1 (en) 2020-09-10
KR102643574B1 (ko) 2024-03-06
KR20240032177A (ko) 2024-03-08
BR112017023171A2 (pt) 2018-07-17
US11000559B2 (en) 2021-05-11
LT3288573T (lt) 2020-03-25
BR122018004815A2 (pt) 2019-09-10
PL3288573T3 (pl) 2020-05-18
WO2016174200A1 (en) 2016-11-03
AU2016256582A1 (en) 2017-11-16
MY183703A (en) 2021-03-09
CN108396015A (zh) 2018-08-14
CN108396015B (zh) 2022-02-18
CA2984038A1 (en) 2016-11-03
US20180042973A1 (en) 2018-02-15
JP6931229B2 (ja) 2021-09-01
HUE048320T2 (hu) 2020-07-28
HK1249009A1 (en) 2018-10-26
US20190076493A1 (en) 2019-03-14
KR102854512B1 (ko) 2025-09-04
AU2018201446B2 (en) 2020-05-28
EP3391892A1 (en) 2018-10-24
AU2016256582B2 (en) 2020-10-29
AU2018201446A1 (en) 2018-03-29
CO2017010831A2 (es) 2018-02-28
CY1122833T1 (el) 2021-05-05
EA037611B1 (ru) 2021-04-21
DK3288573T3 (da) 2020-03-16
JP2018139586A (ja) 2018-09-13
SG11201708604TA (en) 2017-11-29
JP2021176339A (ja) 2021-11-11
EP3288573A1 (en) 2018-03-07
IL258044B (en) 2021-07-29
IL258044A (en) 2018-05-31
ES2780366T3 (es) 2020-08-25
SMT202000222T1 (it) 2020-05-08
IL255286A0 (en) 2017-12-31
SI3288573T1 (sl) 2020-06-30
US10548929B2 (en) 2020-02-04
CL2018000587A1 (es) 2018-08-10
JP2018514199A (ja) 2018-06-07
AU2016256582A8 (en) 2018-01-18
CN107690479B (zh) 2022-02-18
RS60105B1 (sr) 2020-05-29
US20180140649A1 (en) 2018-05-24
US20170266243A1 (en) 2017-09-21
PH12017501942A1 (en) 2018-03-19
IL284375A (en) 2021-07-29
KR20180118249A (ko) 2018-10-30
US20170056458A1 (en) 2017-03-02
PE20180241A1 (es) 2018-01-31
KR20250134212A (ko) 2025-09-09
US10849945B2 (en) 2020-12-01
ZA201801589B (en) 2019-10-30
EP3288573B1 (en) 2020-02-12

Similar Documents

Publication Publication Date Title
CL2017002731A1 (es) Adenovirus oncolítico que codifica una proteína b7
CO2018005945A2 (es) Adenovirus del grupo b que codifica un anticuerpo contra el complejo tcr o fragmento de este
PE20190563A1 (es) Genes de mini-distrofina optimizados y casetes de expresion y su uso
CL2023000264A1 (es) Nuevos vectores virales adeno-asociados dirigidos al hígado
CL2019000392A1 (es) Métodos para detectar aav.
MX2024008058A (es) Adenovirus modificados.
CL2018001522A1 (es) Focalización de péptidos para dirigir virus adenoasociados (aavs)
UY35964A (es) Anticuerpos humanos para pd?1
MX2018007237A (es) Proteinas de cápside modificadas para un suministro mejorado de vectores de parvovirus.
CO2018000134A2 (es) Factor ix modificado, y composiciones para la transferencia de genes a células, órganos y tejidos
CL2017002422A1 (es) Derivados de maitansinoide, conjugados de los mismos, y métodos de uso.
ECSP17059343A (es) ARNi VARIANTE
MX382337B (es) Terapia génica de globina y uso de la misma para el tratamiento de hemoglobinopatias.
MX2019006010A (es) Administracion viral de neoantigenos.
CL2018000740A1 (es) Vectores del factor viii del virus adeno-asociado, partículas víricas asociadas y formulaciones terapéuticas que los comprenden
MX2019001672A (es) Composiciones de poxvirus quiméricos y usos de las mismas.
AR100419A1 (es) Vectores de virus adenoasociados para el tratamiento de trastornos de almacenamiento lisosómico
ECSP19018654A (es) Anticuerpos contra el virus del dengue, polipeptidos que contienen regiones fc variantes, y métodos de uso
IL270876A (en) Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells
UY36522A (es) Ultracentrifugación analítica para la caracterización de partículas virales recombinantes
AR113134A1 (es) Arni variante
EA201890595A1 (ru) Онколитический аденовирус, кодирующий белок b7
MY185846A (en) Oncolytic adenovirus encoding a b7 protein
AR094912A1 (es) Vacuna contra el virus de la leucemia bovina
BR112019001737A2 (pt) expressão de pten-long com vírus oncolíticos